Analysis and Commentary STEVEN GROSSMAN 3/6/21 Analysis and Commentary STEVEN GROSSMAN 3/6/21 Critical Supply Chains and the FDA Read More Advocacy at a Glance STEVEN GROSSMAN 9/18/20 Advocacy at a Glance STEVEN GROSSMAN 9/18/20 Dr. Cavazzoni and Dr. Stein to Address FDA Members and Media on October 16 Read More Advocacy at a Glance STEVEN GROSSMAN 7/26/20 Advocacy at a Glance STEVEN GROSSMAN 7/26/20 House Appropriations Minibus Containing FY 21 Ag/FDA Funding Advances Read More Advocacy at a Glance STEVEN GROSSMAN 3/27/20 Advocacy at a Glance STEVEN GROSSMAN 3/27/20 FDA Gains $80 Million in Third Pandemic Relief Bill Read More Analysis and Commentary STEVEN GROSSMAN 4/13/18 Analysis and Commentary STEVEN GROSSMAN 4/13/18 CBER Today and Tomorrow: Challenges and Opportunities Read More Analysis and Commentary STEVEN GROSSMAN 1/13/18 Analysis and Commentary STEVEN GROSSMAN 1/13/18 Keeping Up with Progress Costs Money! Read More
Analysis and Commentary STEVEN GROSSMAN 3/6/21 Analysis and Commentary STEVEN GROSSMAN 3/6/21 Critical Supply Chains and the FDA Read More
Advocacy at a Glance STEVEN GROSSMAN 9/18/20 Advocacy at a Glance STEVEN GROSSMAN 9/18/20 Dr. Cavazzoni and Dr. Stein to Address FDA Members and Media on October 16 Read More
Advocacy at a Glance STEVEN GROSSMAN 7/26/20 Advocacy at a Glance STEVEN GROSSMAN 7/26/20 House Appropriations Minibus Containing FY 21 Ag/FDA Funding Advances Read More
Advocacy at a Glance STEVEN GROSSMAN 3/27/20 Advocacy at a Glance STEVEN GROSSMAN 3/27/20 FDA Gains $80 Million in Third Pandemic Relief Bill Read More
Analysis and Commentary STEVEN GROSSMAN 4/13/18 Analysis and Commentary STEVEN GROSSMAN 4/13/18 CBER Today and Tomorrow: Challenges and Opportunities Read More
Analysis and Commentary STEVEN GROSSMAN 1/13/18 Analysis and Commentary STEVEN GROSSMAN 1/13/18 Keeping Up with Progress Costs Money! Read More
